Bicara Therapeutics Inc. Common Stock (BCAX) vs STAAR Surgical Company (STAA)

A side-by-side comparison of Bicara Therapeutics Inc. Common Stock and STAAR Surgical Company across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Bicara Therapeutics Inc. Common Stock logo
BCAX
Bicara Therapeutics Inc. Common Stock
$1.09B
$16.56HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
STAAR Surgical Company logo
STAA
STAAR Surgical Company
$1.10B
$22.15HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — BCAX vs STAA

growth of $100 · dividends reinvested · last 2y
BCAX -26.1% (-14.1%/yr)STAA -27.7% (-14.9%/yr)BCAX compounded faster over this window
406080100120Start $10020252026$74$72
BCAX STAA

BCAX vs STAA: by the numbers

  • •STAA is the larger company ($1.10B vs $1.09B market cap).
  • •STAA is profitable (1.13% net margin) while BCAX runs a net loss (0.00%).

Metrics side by side

Valuation

MetricBCAXSTAA
P/E ratioN/A276.87
Forward P/EN/A76.31
P/S ratioN/A3.25
P/B ratio2.323.02
EV / EBITDAN/A22.47

Profitability

MetricBCAXSTAA
Gross margin0.00%76.23%
Operating margin0.00%-19.19%
Net margin0.00%1.13%
ROE-39.54%1.05%
ROIC-42.98%4.80%

Growth (annualized)

MetricBCAXSTAA
Revenue CAGR (5Y)N/A10.49%
Total return CAGR (5Y)N/A-28.41%

Frequently asked

Is BCAX or STAA more profitable?
STAA runs the higher net margin — BCAX at 0.00% versus STAA at 1.13%.

Go deeper

Full BCAX analysisFull STAA analysisInteractive comparison tool

Dig into the metrics

STAAR Surgical P/E ratioBicara Therapeutics Inc. Common Stock ROESTAAR Surgical ROEBicara Therapeutics Inc. Common Stock operating marginSTAAR Surgical operating marginBicara Therapeutics Inc. Common Stock revenue growthSTAAR Surgical revenue growthBicara Therapeutics Inc. Common Stock free cash flowSTAAR Surgical free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.